{"id":"low-tacrolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Gingival hyperplasia"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12 and inhibits calcineurin phosphatase activity, preventing dephosphorylation and nuclear translocation of NFAT transcription factors. This blocks IL-2 and other cytokine production critical for T-cell proliferation. Low-dose formulations aim to maintain therapeutic immunosuppression while reducing nephrotoxicity and other dose-dependent adverse effects.","oneSentence":"Low-dose tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby reducing immune-mediated rejection and inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:23.484Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver)"},{"name":"Autoimmune and inflammatory conditions (atopic dermatitis, eczema)"}]},"trialDetails":[{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT05707377","phase":"PHASE2, PHASE3","title":"A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-04-17","conditions":"Primary Membranous Nephropathy","enrollment":178},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT06552169","phase":"PHASE2","title":"REgulatory T Cell Therapy to Achieve Immunosuppression REduction","status":"RECRUITING","sponsor":"Singulera Therapeutics Inc.","startDate":"2025-06-13","conditions":"Kidney Transplantation","enrollment":34},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT03178149","phase":"PHASE1","title":"A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Institute for Regenerative Medicine","startDate":"2018-07-13","conditions":"Age-Related Macular Degeneration","enrollment":42},{"nctId":"NCT07249346","phase":"PHASE2","title":"Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hannah Choe, MD","startDate":"2026-06-01","conditions":"Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia","enrollment":124},{"nctId":"NCT07290777","phase":"PHASE2","title":"VEL-101 to Prevent Rejection After Kidney Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Veloxis Pharmaceuticals","startDate":"2026-07","conditions":"Transplantation, Kidney","enrollment":120},{"nctId":"NCT07285070","phase":"PHASE2","title":"Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis","status":"NOT_YET_RECRUITING","sponsor":"Novaliq GmbH","startDate":"2026-03","conditions":"Non-infectious Anterior Uveitis","enrollment":20},{"nctId":"NCT06926595","phase":"PHASE2","title":"Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-02-01","conditions":"Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation","enrollment":41},{"nctId":"NCT04232085","phase":"PHASE2","title":"Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-02-12","conditions":"Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure","enrollment":27},{"nctId":"NCT07239128","phase":"EARLY_PHASE1","title":"Photobiomodulation in Combination With Topical Cyclosporine A or Tacrolimus","status":"COMPLETED","sponsor":"University of Seville","startDate":"2024-05-01","conditions":"Dry Eye Disease (DED)","enrollment":160},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT04339777","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases","enrollment":66},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT01889381","phase":"PHASE2","title":"Human Craniomaxillofacial Allotransplantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2012-08","conditions":"Facial Injuries, Traumatic Wounds and Injuries, Craniofacial Injuries","enrollment":15},{"nctId":"NCT07033858","phase":"NA","title":"Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-03-01","conditions":"Kidney Transplant; Complications","enrollment":50},{"nctId":"NCT03726307","phase":"PHASE1","title":"Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Angus W. Thomson PhD DSc","startDate":"2019-04-10","conditions":"Kidney Transplant, Renal Transplant Recipients","enrollment":28},{"nctId":"NCT06235892","phase":"PHASE3","title":"Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-12-10","conditions":"Organ Grafts","enrollment":332},{"nctId":"NCT02220985","phase":"PHASE2","title":"Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-02-03","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":84},{"nctId":"NCT01459107","phase":"PHASE2","title":"Human Upper Extremity Allotransplantation","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2011-07-21","conditions":"Amputation, Traumatic, Wounds and Injuries, Hand Injuries","enrollment":30},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":"Kidney Transplantation","enrollment":126},{"nctId":"NCT04646356","phase":"PHASE2","title":"Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-10-20","conditions":"Hereditary Hemorrhagic Telangiectasia, Epistaxis Nosebleed","enrollment":10},{"nctId":"NCT05975450","phase":"PHASE1","title":"Subcutaneous Abatacept in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Idelberto Badell","startDate":"2023-08-02","conditions":"Kidney Transplant Recipient","enrollment":14},{"nctId":"NCT04665310","phase":"PHASE4","title":"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-09-01","conditions":"Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant","enrollment":46},{"nctId":"NCT01265537","phase":"NA","title":"A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-06-24","conditions":"Acute Graft Rejection, Diabetes","enrollment":30},{"nctId":"NCT06676696","phase":"PHASE4","title":"Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","status":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2024-01-22","conditions":"Renal Failure , Chronic, Graft Failure, Graft Rejection","enrollment":202},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT01763580","phase":"PHASE4","title":"A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2012-07-16","conditions":"MCNS, Minimal Change Nephrotic Syndrome (MCNS)","enrollment":144},{"nctId":"NCT01002339","phase":"PHASE4","title":"Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation","status":"TERMINATED","sponsor":"Armando Torres Ramírez","startDate":"2010-02","conditions":"Diabetes Mellitus, Adult-Onset","enrollment":134},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT06490562","phase":"NA","title":"Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-07","conditions":"Acute Graft-versus-host Disease","enrollment":66},{"nctId":"NCT03605654","phase":"PHASE2, PHASE3","title":"Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants","status":"WITHDRAWN","sponsor":"Medeor Therapeutics, Inc.","startDate":"2024-12","conditions":"Kidney Transplant Rejection","enrollment":""},{"nctId":"NCT06405100","phase":"PHASE3","title":"Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-05","conditions":"Minimal Change Disease","enrollment":81},{"nctId":"NCT06306989","phase":"","title":"Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT","status":"RECRUITING","sponsor":"Cao Weijie","startDate":"2023-01-01","conditions":"Letemovir for the Prevention of CMV Infection After Allo-HSCT","enrollment":150},{"nctId":"NCT04220008","phase":"PHASE2","title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-29","conditions":"Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma","enrollment":""},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT03734601","phase":"PHASE2","title":"Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-11-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder","enrollment":22},{"nctId":"NCT04936282","phase":"PHASE4","title":"Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)","status":"UNKNOWN","sponsor":"Fundación Canaria de Investigación Sanitaria","startDate":"2022-07-05","conditions":"Kidney Transplant Failure and Rejection","enrollment":80},{"nctId":"NCT03386539","phase":"PHASE3","title":"Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2018-01-29","conditions":"Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases","enrollment":211},{"nctId":"NCT01951885","phase":"PHASE3","title":"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-07-07","conditions":"Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT00905515","phase":"PHASE4","title":"Optima: Optimizing Prograf Therapy in Maintenance Allografts II","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2003-08","conditions":"Kidney Transplantation","enrollment":63},{"nctId":"NCT06000982","phase":"PHASE3","title":"Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-10-01","conditions":"GVHD","enrollment":138},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT04258423","phase":"PHASE3","title":"Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function","status":"TERMINATED","sponsor":"Indiana University","startDate":"2019-12-19","conditions":"Kidney Failure","enrollment":4},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT02341274","phase":"PHASE1","title":"Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-11-11","conditions":"Bioequivalence","enrollment":24},{"nctId":"NCT05423496","phase":"NA","title":"KidneyCare Immuno-optimization in Renal Allografts (KIRA)","status":"WITHDRAWN","sponsor":"CareDx","startDate":"2022-08","conditions":"Kidney Transplant, Immunosuppression, Allograft","enrollment":""},{"nctId":"NCT05667922","phase":"","title":"Prognostic Model of TAC in the Treatment of MN","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-06","conditions":"Idiopathic Membranous Nephropathy","enrollment":50},{"nctId":"NCT05667896","phase":"","title":"Prognostic Model of GC/TAC in the Treatment of MN","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-06","conditions":"Idiopathic Membranous Nephropathy","enrollment":50},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT00912223","phase":"PHASE2","title":"Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2009-04","conditions":"Lymphoma, Non-Hodgkin","enrollment":65},{"nctId":"NCT02918292","phase":"PHASE2","title":"Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-07-03","conditions":"Severe Aplastic Anemia","enrollment":32},{"nctId":"NCT04532710","phase":"PHASE2","title":"Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis","status":"COMPLETED","sponsor":"Marinomed Biotech AG","startDate":"2020-08-04","conditions":"Allergic Conjunctivitis, Allergic Rhinitis","enrollment":64},{"nctId":"NCT03672110","phase":"PHASE3","title":"Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen","status":"UNKNOWN","sponsor":"Technische Universität Dresden","startDate":"2014-09","conditions":"Renal Failure, Renal Insufficiency, Renal Disease","enrollment":400},{"nctId":"NCT00579527","phase":"PHASE1, PHASE2","title":"Phase I/II Thymus Transplantation With Immunosuppression #950","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2005-12-19","conditions":"DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly","enrollment":14},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT01958190","phase":"PHASE4","title":"Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2011-02-07","conditions":"Liver Disease","enrollment":196},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT04263519","phase":"PHASE2","title":"A Pilot Open Labeled Study of Tacrolimus in Alzheimer's Disease.","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2021-12-01","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":""},{"nctId":"NCT01663766","phase":"PHASE1","title":"Phase I Study of Milatuzumab for Graft Versus Host Disease","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-12","conditions":"GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome","enrollment":12},{"nctId":"NCT05011916","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2021-08-10","conditions":"Corneal Neovascularization","enrollment":60},{"nctId":"NCT00919503","phase":"PHASE2","title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-07-31","conditions":"Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":98},{"nctId":"NCT00860574","phase":"PHASE2","title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":96},{"nctId":"NCT04118075","phase":"PHASE2","title":"PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2019-01-01","conditions":"GVHD, Acute","enrollment":23},{"nctId":"NCT01685411","phase":"NA","title":"Busulfan and Cyclophosphamide Followed By ALLO BMT","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT04768465","phase":"","title":"Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2021-01-01","conditions":"Myasthenia Gravis","enrollment":160},{"nctId":"NCT04765826","phase":"NA","title":"Comparison Between Systemic Steroids, Topical Steroids, or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-01-25","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT04114188","phase":"PHASE2","title":"Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2016-12-15","conditions":"Renal Transplant Rejection","enrollment":68},{"nctId":"NCT00358657","phase":"PHASE2","title":"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-05-24","conditions":"Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder","enrollment":14},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527},{"nctId":"NCT01095172","phase":"PHASE4","title":"RituxiMab INDuction in Renal Transplantation","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2010-11","conditions":"Function of Renal Transplant","enrollment":100},{"nctId":"NCT03292445","phase":"EARLY_PHASE1","title":"Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation","status":"UNKNOWN","sponsor":"Samuel Strober","startDate":"2017-02-14","conditions":"Immune Tolerance","enrollment":24},{"nctId":"NCT00041288","phase":"PHASE2","title":"Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2001-10","conditions":"Leukemia, Lymphoma","enrollment":10},{"nctId":"NCT00656266","phase":"PHASE4","title":"Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2004-11","conditions":"End-stage Liver Disease, Renal Insufficiency, Renal Failure","enrollment":13},{"nctId":"NCT01529827","phase":"PHASE2","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2012-02-28","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":94},{"nctId":"NCT00434811","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Type 1 Diabetes Mellitus","enrollment":48},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT03864250","phase":"NA","title":"Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-11-26","conditions":"Tacrolimus, Idiopathic Membranous Nephropathy, Clinical Trial","enrollment":124},{"nctId":"NCT01878786","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys","status":"TERMINATED","sponsor":"Matthew Cooper","startDate":"2013-06","conditions":"Delayed Graft Function","enrollment":25},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT00928018","phase":"PHASE3","title":"Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2009-06","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":139},{"nctId":"NCT02166177","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2014-06","conditions":"End-stage Liver Disease","enrollment":9},{"nctId":"NCT00970073","phase":"NA","title":"Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2009-08","conditions":"Liver Transplantation","enrollment":30},{"nctId":"NCT02029638","phase":"PHASE2","title":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-07","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT00331162","phase":"PHASE4","title":"Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2005-02","conditions":"Graft Rejection","enrollment":222},{"nctId":"NCT01208896","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2011-02-03","conditions":"Lymphoma, Follicular, Stem Cell Transplantation","enrollment":32},{"nctId":"NCT02096107","phase":"PHASE4","title":"Novartis Everolimus Transition","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2014-02","conditions":"Graft Dysfunction, Interstitial Fibrosis","enrollment":60},{"nctId":"NCT02702960","phase":"PHASE2","title":"Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03","conditions":"Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT00622895","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-09-01","conditions":"Systemic Scleroderma, Severe Systemic Sclerosis","enrollment":3},{"nctId":"NCT02877082","phase":"PHASE2","title":"Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":5},{"nctId":"NCT01649609","phase":"NA","title":"Using mTOR Inhibitors in the Prevention of BK Nephropathy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-03","conditions":"BK Viremia, BK Nephropathy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low Prograf"],"phase":"marketed","status":"active","brandName":"Low Tacrolimus","genericName":"Low Tacrolimus","companyName":"Ronaldo de Matos Esmeraldo, MD","companyId":"ronaldo-de-matos-esmeraldo-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby reducing immune-mediated rejection and inflammation. Used for Organ transplant rejection prophylaxis (kidney, heart, liver), Autoimmune and inflammatory conditions (off-label use in some settings).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}